Jun 27, 2024, 02:57
Mrinal Patnaik: ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact
Mrinal Patnaik, Physician Scientist with the Division of Hematology, Department of Internal Medicine at Mayo Clinic, Minnesota, shared a post on X:
“ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions.”
Source: Mrinal Patnaik/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 22, 2024, 00:56
Oct 22, 2024, 00:49
Oct 22, 2024, 00:40
Oct 22, 2024, 00:34
Oct 22, 2024, 00:24
Oct 21, 2024, 19:26
Oct 21, 2024, 19:21